Toward Drug Repurposing in Epigenetics: Olsalazine as a Hypomethylating Compound Active in a Cellular Context
Abbreviated Journal Title
ChemMedChem
Keywords
cancer; DNA methylation; drug discovery; drug repurposing; hypomethylating agents; similarity searching; DNA METHYLTRANSFERASE INHIBITORS; TUMOR-SUPPRESSOR GENES; HUMAN CANCER; METHYLATION; DISCOVERY; DNMT1; REPAIR; CELLS; ASSAY; IDENTIFICATION; Chemistry, Medicinal; Pharmacology & Pharmacy
Abstract
DNA hypomethylating drugs that act on DNA methyltransferase (DNMT) isoforms are promising anticancer agents. By using a well-characterized live-cell system to measure DNA methylation revisions (imprints), we characterize olsalazine, an approved anti-inflammatory drug, as a novel DNA hypomethylating agent. The cell-based screen used in this work is highly tractable, internally controlled, and well-suited for a drug repurposing strategy in epigenetics. Olsalazine very closely mimics the action of 5-aza-2-deoxycytidine, a known hypomethylating drug, with minimal cytotoxicity at the concentrations tested. Olsalazine was identified by a rapid computer-guided similarity search of a database of approved drugs to a previously identified inhibitor of DNMTs.
Journal Title
Chemmedchem
Volume
9
Issue/Number
3
Publication Date
1-1-2014
Document Type
Article
Language
English
First Page
560
Last Page
565
WOS Identifier
ISSN
1860-7179
Recommended Citation
"Toward Drug Repurposing in Epigenetics: Olsalazine as a Hypomethylating Compound Active in a Cellular Context" (2014). Faculty Bibliography 2010s. 5829.
https://stars.library.ucf.edu/facultybib2010/5829
Accessibility Statement
This item was created or digitized prior to April 24, 2027, or is a reproduction of legacy media created before that date. It is preserved in its original, unmodified state specifically for research, reference, or historical recordkeeping. In accordance with the ADA Title II Final Rule, the University Libraries provides accessible versions of archival materials upon request. To request an accommodation for this item, please submit an accessibility request form.
Comments
Authors: contact us about adding a copy of your work at [email protected]